bey2153
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 28, 2020 (NCT04476303)
Timeline
Indications
Studied for
Mechanism of action
- Microtubule-associated protein tauINHIBITOR
MAPT inhibitor
- Beta amyloid A4 proteinINHIBITOR
APP inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06885567 | Phase 2 | Jul 31, 2025 | BeyondBio Inc. |
| NCT04476303 | Phase 1 | Aug 28, 2020 | BeyondBio Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BeyondBio Inc. | For profit | 2 | 2 | 2 | 2020 |
1 organizations
Page 1 / 1